Clinical Trial Detail

NCT ID NCT03462719
Title A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

chronic lymphocytic leukemia

CLL/SLL

Therapies

Chlorambucil + Obinutuzumab

Ibrutinib + Venetoclax

Age Groups: senior adult

No variant requirements are available.